Cost-effectiveness of umeclidinium/vilanterol combination therapy compared to tiotropium monotherapy among symptomatic patients with chronic obstructive pulmonary disease in the UK

BACKGROUND: The cost-effectiveness of umeclidinium bromide-vilanterol (UMEC/VI) versus tiotropium monotherapy in the UK was assessed using a UMEC/VI treatment-specific economic model based on a chronic obstructive pulmonary disease (COPD) disease-progression model. METHODS: The model was implemented...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Cost Eff Resour Alloc
Päätekijät: Punekar, Yogesh Suresh, Roberts, Graeme, Ismaila, Afisi, O’Leary, Martin
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: BioMed Central 2015
Aiheet:
Research
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4676898/
https://ncbi.nlm.nih.gov/pubmed/26692823
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12962-015-0048-6
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia